À LA UNE de l'actualité médicale
Glaucoma is the leading cause of global intractable blindness and it is expected to affect 76 million patients in 2020 (Tham et al., 2014). Worldwide, 4.5 million cases of moderate or severe visual impairment and 3 million cases of blindness are ascribed to glaucoma (Flaxman et al., 2017). Glaucoma denotes optic neuropathies characterized by progressive degeneration of retinal ganglion cells, often...
Andrim Halili et al.
Acta Ophthalmologica Scandinavica 2020; AOP: 10.1111/aos.14452
Lire la suite
Andrim Halili et al.
Acta Ophthalmologica Scandinavica 2020; AOP: 10.1111/aos.14452
Lire la suite
Macular edema (ME) is a leading cause of vision loss among many patients with diabetic retinopathy (DR) [1], retinal vein occlusion (RVO) [2], and uveitis [3]. Preserving vision is the primary of treating ME, and testing visual function is an important tool in assessing successful treatment. Best corrected visual acuity (BCVA) is the most commonly used functional outcome measure of treating ME, both...
Lazha Sharief et al.
Graefe's Archive for Clinical and Experimental Ophthalmology 2020; aop: 10.1007/s00417-020-04715-7
Lire la suite
Lazha Sharief et al.
Graefe's Archive for Clinical and Experimental Ophthalmology 2020; aop: 10.1007/s00417-020-04715-7
Lire la suite
Glaucomatous optic neuropathy is associated with various morphologic changes to the optic nerve head (ONH). Such changes include both development and enlargement of beta-zone parapapillary atrophy (β-zone PPA), as characterised by atrophy of the retinal pigment epithelium, photoreceptors and choriocapillaris, and which results in distinctive sclera and choroidal vessel appearances.1 2
The spatial...
Ahnul Ha et al.
British Journal of Ophthalmology 2020; aop:10.1136/bjophthalmol-2019-315477
Lire la suite
Ahnul Ha et al.
British Journal of Ophthalmology 2020; aop:10.1136/bjophthalmol-2019-315477
Lire la suite
